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Candida auris is a multidrug-resistant yeast that causes a wide spectrum of infections, especially in intensive care settings. We
investigated C. auris prevalence among 102 clinical isolates previously identified as Candida haemulonii or Candida famata by
the Vitek 2 system. Internal transcribed spacer region (ITS) sequencing confirmed 88.2% of the isolates as C. auris, and matrix-
assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOFMS) easily separated all related species, viz.,
C. auris (n 90), C. haemulonii (n 6), C. haemulonii var. vulnera (n 1), and Candida duobushaemulonii (n 5). The in
vitro antifungal susceptibility was determined using CLSI broth microdilution (CLSI-BMD), the Vitek 2 antifungal susceptibility
test, and the Etest method. C. auris isolates revealed uniformly elevated fluconazole MICs (MIC50, 64g/ml), and an alarming
percentage of isolates (37%) exhibited elevated caspofungin MICs by CLSI-BMD. Notably, 34% of C. auris isolates had coexist-
ing elevatedMICs (>2g/ml) for both fluconazole and voriconazole, and 10% of the isolates had elevated coexistingMICs (>2
g/ml) to two additional azoles, i.e., posaconazole and isavuconazole. In contrast to reduced amphotericin BMICs by CLSI-
BMD (MIC50, 1g/ml) for C. auris, elevated MICs were noted by Vitek 2 (MIC50, 8g/ml), which were statistically significant.
Candida auris remains an unnoticed pathogen in routine microbiology laboratories, as 90% of the isolates characterized by
commercial identification systems are misidentified as C. haemulonii. MALDI-TOFMS proved to be a more robust diagnostic
technique for rapid identification of C. auris. Considering that misleading elevated MICs of amphotericin B by the Vitek AST-
YS07 card may lead to the selection of inappropriate therapy, a cautionary approach is recommended for laboratories relying on
commercial systems for identification and antifungal susceptibility testing of rare yeasts.
In recent years, two species, namely, Candida pseudohaemuloniiand Candida auris, which are phylogenetically closely related to
Candida haemulonii in the Metschnikowiaceae clade, have been
described (1). The yeast C. auris, isolated from the external ear
canal of a Japanese patient, was described as a new species in 2009
(2). This pathogen was recently recognized as an emerging multi-
drug-resistant (MDR) yeast that can cause a wide spectrum of
infections, ranging from fungemia to deep-seated infections, es-
pecially in intensive care settings (3–8). Candida auris is reported
to be misidentified as C. haemulonii, Candida famata, and Rho-
dotorula glutinis by commercial identification systems, such as
Vitek 2 and API20C-AUX, and exhibits a unique susceptibility
profile (5–8). Notably, the potential of clonal transmission of C.
auris, highly elevated MICs to fluconazole, and reduced suscepti-
bility to voriconazole, caspofungin, and flucytosine are matters of
serious concern (7–9). Therefore, accurate identification is im-
portant, because treatment strategies are often directed by species
characterization of Candida. Further, a recent report of mislead-
ingly high MICs of amphotericin B and caspofungin using the
commercially available Vitek 2 automated system in a patient with
pericarditis due toC. auris highlights issues of inappropriate treat-
ment strategies if accurate susceptibility testing is not available (4).
In the present era, molecular techniques and a growing database of
fungal genome sequences have facilitated the reliable identifica-
tion of phylogenetically related and phenotypically identical spe-
cies. Herein, we investigated the prevalence of C. auris in a collec-
tion of clinical isolates previously phenotypically identified as C.
haemulonii/C. famata, using internal transcribed spacer region
(ITS) sequencing and evaluated matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS)
for rapid and reliable identification of this yeast. Further, their in
vitro antifungal susceptibilities to the 10 antifungals were deter-
mined using the CLSI broth microdilution (CLSI-BMD) method,
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and data obtained by CLSI were compared with those obtained by
the commercial Vitek 2 system and the Etest method.
(Part of this study was presented at the Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy [54th ICAAC],
M-1203, slide session, Washington, DC, USA [10].)
MATERIALS AND METHODS
Isolates.Atotalof102clinical isolates, fromindividualpatients,previously iden-
tified as Candida haemulonii/C. famata by the Vitek 2 compact system (bio-
Mérieux, Marcy I’Etoile, France) in 4 tertiary care hospitals in Delhi, North India,
and a single center in Kochi, Kerala, South India, from 2010 to 2014 were in-
cluded. Three centers were about 1,000-bed general hospitals, and the remaining
2 were a pediatric hospital and a transplant center. The pediatric hospital had
neonatal intensivecareunitsandsurgical intensivecarefacilities.Theisolateswere
mainly from patients with candidemia (blood; n  78), and other specimens
from invasive Candida infections included gangrenous tissue (n 4), pleural
fluid (n6), and peritoneal fluid (n7). Also, 7 isolates from urine (n4) and
sputum (n 3) specimens from immunocompromised patients were included.
The control and type strains of three C. auris isolates from Korea (KCTC
17809, KCTC 17810) and Japan (DSM 21092T) and one isolate each of C.
haemulonii strain CBS 7802 and C. duobushaemulonii strain CBS 7798T
were also analyzed.
Phenotypic characterization.The isolates were identified by standard
mycological procedures, including colony color on CHROMagar Can-
dida medium (Difco, Becton Dickinson & Company, Baltimore, MD,
USA) and morphology on rice Tween 80 agar. Growth patterns at differ-
ent temperatures, 37°C, 42°C, and 45°C, were also observed (1). Addition-
ally, the assimilation profile of all yeast isolates was done by commercially
available API strips (ID32C; bioMérieux, Marcy I’Etoile, France), which
were read and interpreted at 48 h.
Sequencing of ITS region. Genomic DNA was extracted from all test
isolates along with reference strains as described by Xu et al. (11). DNA
was amplified and sequenced using the ITS-1 (5=-TCCGTAGGTGAACC
TTGCGG-3=) and ITS-4 (5=-TCCTCCGCTTATTGATATGC-3=) prim-
ers, which amplify the ITS region of the ribosomal subunit (8). Sequences
were aligned, and GenBank Basic Local Alignment Search Tool (BLAST)
searches were performed for species identification. For phylogenetic anal-
yses, the ITS gene sequences of the C. auris, C. haemulonii, and C. duo-
bushaemulonii isolates were aligned with the ClustalW program (version
1.82), and the final alignments were edited manually. A neighbor-joining
(NJ) tree based on ITS gene sequences using 2,000 bootstrap replications
was generated using MEGA version 5 (12). The sequences of the refer-
ence/type strains of C. auris from Japan (JCM 15448T) and Korea (KCTC
17809 and KCTC 17810), along with C. haemulonii (CBS 5150, Portugal;
CBS 7801, United States), C. haemulonii var. vulnera (CNMCL-7462,
Spain), and C. duobushaemulonii (CBS 7799, USA), were retrieved from
GenBank and included for the analysis.
MALDI-TOF MS. The ethanol-formic acid extraction procedure was
followed according to the manufacturer’s protocol for the identification
of yeast isolates (13). The spectra were analyzed using the Flex Control 3.1
software (Bruker Daltonics, Inc., Billerica, MA, USA) and MALDI Bio-
typer OC version 3.1 (Bruker Daltonics, Bremen, Germany). Score values
were analyzed as per manufacturer recommendations: a score of 2 in-
dicated confidence to the species level, 1.7 to 1.99 indicated confidence to
the genus level, and1.7 indicated no identification.
MALDIdata analysis.The MALDI Biotyper version 3 database contains
spectra of 3 strains of C. auris, two from Korea (KCTC 17809 and KCTC
17810) and a type strain from Japan (DSM 21092T). For phylogenetic
analysis, spectra of 90 C. auris isolates were added manually to the library
for the creation of a score-oriented dendrogram in Biotyper as described
previously for Aspergillus species (14). The mass spectra of each quadru-
plicate of the respective isolates with a score value of2 were considered
for dendrogram preparation. Additionally, available spectra of reference
strains ofC. auris from Japan (DSM 21092T) and Korea (KCTC 17809 and
KCTC 17810) and of C. haemulonii (CBS 5149T and CBS 5150), C. duo-
bushaemulonii (CBS 7799 and CBS 7800), and C. pseudohaemulonii (CBS
10004 and CBS 12453T) in the database were imported in the software for
the analysis of the dendrogram. The dendrogram was generated by using
the respective functionality of the MALDI Biotyper 3.1 offline client. The
spectra of all the isolates tested were analyzed by a score-oriented dendro-
gram using an arbitrary distance level of 1,000 as the cutoff.
AST. (i) CLSI-BMDmethod.Antifungal susceptibility testing (AST) was
carried out using the Clinical and Laboratory Standards Institute broth mi-
crodilution method (CLSI-BMD), following the M27-A3 guidelines (15).
Antifungals tested were amphotericin B (AMB; Sigma, St. Louis, MO, USA),
fluconazole (FLU; Pfizer, Groton, CT, USA), itraconazole (ITC; Lee Pharma,
Hyderabad, India), voriconazole (VRC; Pfizer), posaconazole (POS; Merck,
Whitehouse Station, NJ, USA), isavuconazole (ISA; Basilea Pharmaceu-
tica, Basel, Switzerland), flucytosine (5-FC; Sigma), caspofungin (CAS;
Merck), micafungin (MFG; Astellas, Toyama, Japan), and anidulafungin
(AFG; Pfizer). RPMI 1640 medium with glutamine without bicarbonate
(Sigma) buffered to pH 7 with 0.165 mol/liter 3-N-morpholinepropane-
sulfonic acid (MOPS; Sigma) was used. Drug-free and yeast-free controls
were included, and microtiter plates were incubated at 35°C and read
visually after 24 h, as validated recently by Pfaller et al. (16, 17). CLSI-
recommended Candida krusei ATCC 6258 and Candida parapsilosis
ATCC 22019 were used as quality control strains, and two reference
strains of C. auris (KCTC 17809 and DSM 21092T) were also included.
Excepting AMB, the MIC endpoints for all the antifungals were defined as
the lowest drug concentration that caused 50% growth inhibition vis-à-vis
the drug-free controls. The MIC for AMB was defined as the lowest con-
centration at which there was 100% inhibition of growth. The suscepti-
bility for all the isolates was performed by two different personnel on two
occasions, which revealed reproducible results.
(ii) Vitek 2 Compact system using an AST-YS07 card. Susceptibility
was determined using an AST-YS07 card, which tests the MIC of 6 anti-
fungals, i.e., FLU, 5-FC, VRC, AMB, CAS, and MFG. All the C. auris
isolates were tested as per the manufacturer’s instructions. The time of
incubation ranged from 18 to 27 h, based on the rate of growth in the
drug-free control well, and the results were expressed as MICs in micro-
grams per milliliter.
(iii) Etest method. Further, the isolates which revealed 2-fold dis-
crepancies in the antifungal MICs by the above-described two methods
were also tested for susceptibility by Etest using Etest Technical Guide 4:
Antifungal Susceptibility of Yeasts (AB Biodisk, bioMérieux, Solna, Swe-
den), as described previously (19, 20). The antifungals tested were AMB,
CAS, and VRC. Briefly, the inoculum density of 0.5  103 to 2.5  103
cells/ml prepared for the CLSI-BMD test was used, and the test medium
included RPMI 1640 with 1.5% agar supplemented with glucose (2%) and
was buffered to pH 7.0 with MOPS. In addition, AMB was also tested on
antibiotic medium 3 (AM3) agar plates. The plates were inoculated by
dipping a sterile cotton swab into the inoculum and streaking it across the
entire surface of the agar in three directions. The plates were dried for 15
min before the Etest strips (AB Biodisk) were applied and kept at 35°C and
read visually after 24 h. The Etest MIC was defined as the drug concentra-
tion at which the border of the elliptical zone of complete inhibition
intersected the scale on the antifungal test strip.
Statistical analysis. Statistical analyses were performed with SPSS ver-
sion 20.0 (SPSS, Chicago, IL, USA). MIC values from the CLSI-BMD,
Vitek 2, and Etest methods were assessed by using the Student t test
(paired sample). The Etest MIC endpoints, which were in between the
2-fold dilution scale of the CLSI method, were rounded to the corre-
sponding next upper 2-log dilution to simplify comparisons. The discrep-
ancies among MIC endpoints of 2 dilutions (two wells) were used to
calculate the essential agreement (EA).
FKS gene sequencing.Candida auris isolates with elevated CLSI-BMD
MICs of CAS (MICs 1g/ml) were subjected to sequencing of the FKS1
and FKS2 genes. Considering that the genome sequence of C. auris is not
yet available, the published mutations in the FKS gene of echinocandin-
resistant Candida glabrata isolates were used to analyze the mutations in
Kathuria et al.
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the FKS gene of C. auris isolates by sequence homology (21, 22). Genomic
DNA was amplified and sequenced for hot spot regions of both the genes.
The primers were designed based on the C. glabrata FKS1 and FKS2 gene
sequences (GenBank accession no. XM_446406 and XM_448401, respec-
tively). The primers for FKS1 (FKS1HSF, 5=-CATTGCTATTTTTCTCAG
TCATGC-3=; FKS1HSR, 5=-CCAACGGAAAAGACAGTGTTGA-3=) and
FKS2 (FKS2HSF, 5=-CTGTGACATTTTTCATTGCTG-3=; FKS2HSR, 5=-
TCCAAGGAGTTAAGATGGAAATACC-3=) were designed using Primer3
software version 4 (http://primer3.ut.ee/). DNA sequences were analyzed
with Sequencing Analysis software version 5.3.1 (Applied Biosystems). Con-
sensus sequences were made using BioEdit software (version 7.0.5.3) and
were aligned with hot spot FKS regions of reference C. glabrata (GenBank
accession no. HM366439 for FKS1 and HM366442 for FKS2).
Nucleotide sequence accession numbers. The sequences determined
in this study were deposited in GenBank under accession no. KF689009 to
KF689022, KC692039 to KC692052, and KP862745 to KP862818.
RESULTS
Vitek 2 identified 100 isolates as C. haemulonii (88 with 91 to 98%
identity and 12 with a low discrimination profile), whereas the
remaining 2 isolates were identified as C. famata (93% identity).
Of the 102 isolates, 88.2% (n 90) were confirmed as C. auris by
ITS sequencing. The remaining 12 isolates were identified as C.
haemulonii (n  6), C. haemulonii var. vulnera (n  1), and C.
duobushaemulonii (n  5). All C. auris (n  90) isolates showed
smooth, white to cream-colored colonies on Sabouraud dextrose
agar (SDA), whereas they developed a pink color on CHROMagar
Candida medium. Microscopic examination showed ovoid to
elongated budding yeast cells occurring singly or in pairs. No
pseudohyphae were formed on rice Tween 80 agar after 4 to 8 days
of incubation at 28°C. They grew well at 37°C and 42°C. In con-
trast, C. haemulonii and C. duobushaemulonii isolates revealed
pseudohyphae with blastoconidia and did not grow at 42°C. All
the C. auris isolates were positive for assimilation of N-acetylglu-
cosamine, succinate, and gluconate, whereas negative results were
recorded for C. haemulonii and C. duobushaemulonii.
ITS sequences of the 90 isolates (GenBank accession no.
KF689009 to KF689022, KC692039 to KC692052, KP862745 to
KP862805, and KP862818) showed 99% homology (query coverage
ranging from 98 to 100%) withC. auris isolates in GenBank (acces-
sion no. HE797773 and AB375772). However, the ITS sequences
of 6 isolates (GenBank accession no. KP862806 to KP862811)
showed 100% homology with C. haemulonii (GenBank accession
no. KM014586 and JX459689), and 5 isolates (GenBank accession
no. KP862813 to KP862817) showed 100% homology with C.
duobushaemulonii (GenBank accession no. KM361511 and
KJ476202). Also, a solitary isolate (VPCI 715/P/14; GenBank ac-
cession no. KP862812) showed 100% homology with C. haemulonii
var. vulnera (GenBank accession no. JX459686). The ITS tree
yielded 3 distinct clades with a good bootstrap value (99%) and
enabled the differentiation of C. auris from C. haemulonii and C.
duobushaemulonii strains (Fig. 1). All the Indian C. auris (n 90)
strains exhibited 99 to 100% sequence similarity among them-
selves. However, C. auris isolates from Japan and Korea formed a
separate group away from Indian C. auris isolates in the same
clade. The other species of the C. haemulonii complex were well
differentiated in 2 separate clades. Candida duobushaemulonii
(n 5) formed clade 2, whereas Candida haemulonii (n 6) and
C. haemulonii var. vulnera (n 1) formed two groups in clade 3.
MALDI-TOFMS.The MALDI-TOF mass spectra obtained for
all C. auris isolates were evaluated against the original MALDI
Biotyper OC version 3.1 database. The mean MALDI-TOF MS
score of the tested C. auris isolates was 2.167 (range, 2.013 to
2.347). Of the 90 C. auris isolates, the majority (n  77, 85.5%)
were identified to the species level at the first attempt with a score
value of2. The remaining isolates (n 13) were also identified
as C. auris but with a score value of 2 and 1.7. These isolates
were repeated and revealed high score values in the second at-
tempt. All the C. haemulonii (n  6) and C. duobushaemulonii
(n  5) strains were identified to the species level (score value,
2). Further, a solitary isolate of C. haemulonii was also identi-
fied to the variety level with a score value of2 (C. haemulonii var.
vulnera). The dendrogram clearly revealed separation of members
of the Metschnikowiaceae clade in 4 phylogroups (Fig. 2). The
mass spectra of the Indian C. auris isolates showed marked simi-
larity, whereas the Japanese (n  1) and Korean C. auris isolates
(n  2) exhibited variations in mass spectra among themselves
and with those of Indian C. auris isolates, resulting in a separate
cluster inC. auris (phylogroup 4). The dendrogram generated was
in agreement with the phylogenetic NJ tree with ITS sequences.
In vitro susceptibility andFKSmutation analysis.The in vitro
susceptibility data and the MIC distribution of C. auris isolates
using different methods along with essential agreements between
the tested methods are presented in Tables 1 and 2.
CLSI-BMD. FLU exhibited no activity against 89% (n 80) of C.
auris isolates (MIC of 16 to 64 g/ml), whereas the remaining 10
isolates revealed a MIC of 4 g/ml. Similarly, an elevated MIC90, i.e., 8
g/ml, was noted for VRC. Notably, 58% ofC. auris isolates (n 52)
showed VRC MICs of1g/ml. In contrast, MIC50 values of POS
(0.06 g/ml) and ISA (0.25 g/ml) were relatively low compared
to that of VRC (Table 1). Also, 11% of C. auris isolates revealed
MICs of 1 g/ml for both POS and ISA, and a solitary isolate
showed a MIC of 1 g/ml only to ISA. All C. auris isolates
showed reduced MICs to ITC (geometric mean [GM] MIC, 0.15
g/ml). Furthermore,C. auris isolates had AMB MIC50 values of 1
g/ml; however, 15.5% (n 14) of the isolates revealed MICs of
2g/ml for AMB. Moreover, elevated GM MICs were observed
for CAS (0.58 g/ml) in comparison to MFG (0.11 g/ml) and
AFG (0.23 g/ml). Notably, 37% (n 33) of the C. auris isolates
revealed MICs of 1 g/ml to CAS. Also, all the echinocandins
had no activity in 8% (n  7) of the isolates, with MICs ranging
from 4 to 8 g/ml (Table 2). Further, 88% of C. auris isolates
had reduced MICs to 5-FC (GM MIC, 0.4 g/ml), whereas 11
isolates showed highly elevated MICs (32g/ml). In contrast to
C. auris, all the C. haemulonii (n  7) and C. duobushaemulonii
(n 5) isolates had markedly elevated AMB MICs ranging from 4
to 16 g/ml. Also, variable FLU MICs were observed for C.
haemulonii (MIC range, 2 to64 g/ml) and C. duobushaemulo-
nii (MIC range, 1 to 16 g/ml). However, reduced MICs of VRC
(MIC range, 0.03 to 0.5g/ml) were noted for both the C. haemu-
lonii and C. duobushaemulonii isolates, except a solitary isolate of
C. haemulonii, which showed a MIC of 4 g/ml. Moreover, both
the C. haemulonii and C. duobushaemulonii isolates exhibited re-
duced GM MICs to ISA (0.027 g/ml and 0.023 g/ml), followed
by POS (0.05 g/ml and 0.11 g/ml) and ITC (0.31 g/ml). Also,
in contrast to C. auris (GM MIC, 0.58g/ml), both C. haemulonii
(GM MIC, 0.19 g/ml) and C. duobushaemulonii (GM MIC, 0.14
g/ml) showed reduced MICs to CAS. However, a wide MIC
range (0.125 to 64 g/ml) for 5-FC was observed for C. haemu-
lonii, while reduced MICs (GM MIC, 0.125g/ml) were found for
C. duobushaemulonii (Table 1).
Misidentiﬁcation and Susceptibility of C. auris
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FKS gene sequencing ofC. auris isolateswith elevated caspo-
fungin MICs (>1 g/ml). Amplification of FKS1 and FKS2 re-
gions generated amplicons of 391 bp and 460 bp, respectively.
Mutations reported for caspofungin-resistantC. glabratawere not
observed in the FKS1 and FKS2 regions of any of the testedC. auris
strains.
Vitek 2. In contrast to low AMB MICs recorded by CLSI for C.
auris, exceptionally elevated AMB MICs (CLSI MIC50 of 1 g/ml
compared to Vitek MIC50 of 8 g/ml) were noted, which were
statistically significant (P 0.0001). Barring a solitary isolate ofC.
auris, all the other isolates had MICs of 8 g/ml for AMB
(Table 2). Also, the AMB MICs of C. haemulonii and C. duobush-
aemulonii ranged from 8 to 16 g/ml, which was in concordance
with CLSI. Vitek 2 MIC50 values of VRC (1 g/ml), CAS (0.5
g/ml), and MFG (0.125 g/ml) of C. auris isolates were in 100%
agreement with those by the CLSI method. Vitek 2 MIC50 values of
FLU (32 g/ml) and 5-FC (1 g/ml) were within2 dilutions by
CLSI-BMD.
Etest. Similar to CLSI MICs, low MIC50 values of AMB for C.
auris isolates were observed by Etest on AM3 medium (0.5g/ml)
and on RPMI agar (1 g/ml). Except a solitary isolate, all C. auris
isolates showed MICs of 1 g/ml for AMB. The MIC50 (1 g/
FIG 1 Phylogenetic tree based on partial ITS sequences of Indian C. auris (n 90), C. duobushaemulonii (n 5), C. haemulonii (n 6), and C. haemulonii var.
vulnera (n  1) isolates using neighbor-joining analysis with 2,000 bootstrap replications. Sequences of reference strains of Candida haemulonii (CBS 5150,
Portugal; CBS 7801, United States), C. duobushaemulonii (CBS 7799, United States), and C. haemulonii var. vulnera (CNMCL-7462, Spain) along with Japanese
(JCM 15448T) and Korean (KCTC-17809 and KCTC-17810)C. auris isolates were retrieved from GenBank for the analysis. Bootstrap values are shown above the
branches.
FIG 2 Score-oriented dendrogram of the main spectra (MALDI Biotyper 3.1; Bruker Daltonics) by using average linkages clustering the MALDI-TOF spectra
of Indian Candida auris (n 90) along with the C. haemulonii (n 6), C. duobushaemulonii (n 5), and C. haemulonii var. vulnera (n 1) isolates. Candida
auris (DSM 21092T, KCTC-17809, and KCTC-17810) and C. pseudohaemulonii (JCM 12453T and CBS 10004), C. haemulonii (CBS 5150 and CBS 5149T), C.
haemulonii var. vulnera (CL-7073), andC. duobushaemulonii (CBS 7800 and CBS 7799) were added to make the clustering in MALDI-TOF MS more robust. The
isolates were classified into 4 phylogroups. The inset depicts the variation among Indian, Japanese, and Korean C. auris isolates leading to two clusters in
phylogroup 4.
Misidentiﬁcation and Susceptibility of C. auris
June 2015 Volume 53 Number 6 jcm.asm.org 1827Journal of Clinical Microbiology
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
ml) of VRC was similar to that by CLSI-BMD. In contrast, Etest
CAS MICs were better differentiated than CLSI-BMD MICs, and
Vitek showed a wide range from 0.002 to 4 g/ml. Specifically, 33
C. auris isolates which showed MICs of1g/ml for CAS by CLSI
revealed highly variable MICs ranging from 0.064 to 4 g/ml by
Etest. Interestingly, 26 of these 33 isolates revealed MICs of 1
g/ml for CAS by Vitek. The remaining 7 isolates had MICs of 4
g/ml, which were in agreement with the CLSI-BMD MICs. Fur-
ther, Etest MICs of C. haemulonii and C. duobushaemulonii for
AMB, CAS, and VRC were within2 dilutions of CLSI MICs.
Agreement betweenmethods. The essential agreement within
2 dilutions for the comparison of 24-hour CLSI-BMD with Vi-
tek 2 and Etest results showed 10% and 81% for AMB, 90% and
48% for CAS, and 91% and 79% for VRC, respectively.
DISCUSSION
The present study highlights that Candida auris remains an unno-
ticed pathogen in routine microbiology laboratories in India, as
90% of the isolates characterized by commercial identification
systems misidentify this yeast as C. haemulonii. In the past 5 years,
Candida auris has emerged as a significant pathogen in tertiary
care general hospitals and a pediatric center in north and south
India, representing 8.6% to 30% of cases of candidemia (7, 8). The
actual prevalence of C. auris in varied clinical settings in India is
unexplored, as the majority of centers do not perform molecular
or MALDI-TOF MS-based identification. In this work, a large
number ofC. auris isolates were tested for antifungal susceptibility
with three methods which showed uniform fluconazole resistance
and an alarming percentage of isolates (37%) exhibiting elevated
caspofungin MICs by CLSI-BMD. Taken together, 10% of isolates
showed highly elevated MICs to 4 antifungals drugs (AMB, FLU,
CAS, VRC) by the CLSI-BMD method. Notably, 34% of isolates
had coexisting elevated MICs for two commonly used azoles, i.e.,
FLU and VRC (MICs of 2 g/ml), and 10% of the isolates had
elevated coexisting MICs (1g/ml) to two additional azoles, i.e.,
POS and ISA. Considering the frequent prevalence of MDR strains
ofC. auris in the intensive care units and other wards of 5 different
hospitals in the present series, the accurate identification and an-
tifungal susceptibility testing of this yeast is pertinent for guiding
therapy and determining the prognosis in such settings. Also, ac-
curate identification of the cryptic species C. auris is important in
assessing the epidemiology and pathogenicity of the disease
TABLE 1 In vitro antifungal susceptibility profile of C. auris, C. haemulonii, and C. duobushaemulonii strains by the CLSI M27-A3 broth
microdilution method
Species tested
MIC
parameter
MIC (g/ml)a
AMB ITC VRC ISA POS FLU 5-FC CAS MFG AFG
C. auris (n 90 isolates) GM 0.8 0.15 1.01 0.18 0.06 36 0.5 0.58 0.11 0.23
MIC50 1 0.125 1 0.25 0.06 64 0.25 0.5 0.125 0.125
MIC90 4 0.5 8 2 2 64 8 1 0.25 0.5
MIC range 0.125–8 0.03–2 0.03–16 0.015–4 0.015–8 4–64 0.125–64 0.125–8 0.015–8 0.015–8
C. haemulonii
(n 7 isolates)
GM 12.7 0.314 0.31 0.027 0.05 32 2.82 0.19 0.28 0.44
MIC50 16 0.25 0.5 0.015 0.125 64 32 0.25 0.25 0.5
MIC90 16 0.5 2 0.25 0.25 64 64 1 1 1
MIC range 4–16 0.25–0.5 0.03–4 0.015–0.5 0.015–0.25 2–64 0.125–64 0.06–1 0.125–1 0.25–1
C. duobushaemulonii
(n 5 isolates)
GM 16 0.315 0.068 0.023 0.11 6.35 0.125 0.14 0.35 0.56
MIC50 16 0.25 0.06 0.015 0.125 8 0.125 0.125 0.5 0.5
MIC90 16 0.5 0.125 0.06 0.25 16 0.125 0.25 1 1
MIC range 16 0.25–0.5 0.03–0.125 0.015–0.06 0.03–0.125 1–16 0.125 0.06–0.25 0.125–1 0.5–1
a AMB, amphotericin B; ITC, itraconazole; VRC, voriconazole; ISA, isavuconazole; POS, posaconazole; FLU, fluconazole; 5-FC, 5-flucytosine; CAS, caspofungin; MFG, micafungin;
AFG, anidulafungin.
TABLE 2 Distribution of MICs of amphotericin B, caspofungin, and voriconazole obtained by 3 different methods for Candida auris (n 90)
strains
Drug testeda Test method
No. of isolates at MIC (g/ml) MIC (g/ml)
0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 16 MIC50 MIC90
AMB CLSI-BMD 2 16 23 35 4 6 4 1 4
Vitek 2 1 48 41 8 16
Etest 5 1 4 25 54 1 0.5 1
CAS CLSI-BMD 1 29 27 25 1 4 3 0.5 1
Vitek 2 21 34 28 7 0.5 4
Etest 9 1 9 22 33 5 4 7 0.25 2
VRC CLSI-BMD 1 4 7 8 18 17 18 6 3 3 5 1 8
Vitek 2 3 5 12 28 16 14 10 2 1 4
Etest 1 3 2 8 15 36 12 3 7 3 1 16
a AMB, amphotericin B; CAS, caspofungin; VRC, voriconazole.
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caused by this underreported pathogen in different geographic
areas. In the past 5 years,C. auris fungemia has been reported from
South Africa, South Korea, Japan, and India (3, 5–8). All of the
reports from these countries confer the major issue of notable
elevated MICs for azoles and caspofungin in C. auris and its mis-
identification by phenotypic methods. The present study em-
ployed MALDI-TOF MS, a more robust diagnostic technique, for
rapid identification. The strength of the present study is that it
developed a comprehensive reference database built with a large
number of molecularly characterized C. auris strains from differ-
ent geographical regions of India to supplement the Bruker Bio-
typer library, which has a database of only 3 strains from Korea
and Japan. Not only was interspecies differentiation well charac-
terized, but also the mass spectra variation at the intraspecies level
separated C. auris isolates from India. It is pertinent to mention
here that, previously, IndianC. auris isolates have been reported to
exhibit differences in biochemical profiles compared to the Japa-
nese and the Korean C. auris isolates (7, 8). Similarly, genotypic
variation among C. auris isolates from different geographical re-
gions has also been observed with M13 fingerprinting and ampli-
fied fragment length polymorphism analysis (7). It is evident from
the present study that the high resolution and discriminatory
power of MALDI-TOF MS facilitate differentiation of closely re-
lated cryptic species within the Metschnikowiaceae clade (23),
which has also been documented previously for Mucorales, par-
ticularly the Lichtheimia species (24).
Another issue of concern is the misleading highly elevated
MICs of AMB with Vitek automated readings in all C. auris iso-
lates tested. The overall EA between Vitek automated readings and
the CLSI-BMD method for AMB was very low (10%). Notably, the
reference CLSI-BMD method in the present series showed re-
duced AMB MICs in 84% of C. auris isolates. Similarly, low AMB
MICs (0.25 to 1 g/ml) by CLSI-BMD were reported for 20 C.
auris isolates from South Korea by Shin et al. (25). However, these
authors observed a high EA (100%) between the CLSI-BMD and
Vitek method for AMB, which is in contrast with the observations
in the present study. This deviation could be attributed to the low
number of isolates tested (25). Major errors of azole susceptibility
in 218 isolates of 5 Candida species using another commercial
automated reading system (ATB FUNGUS 3) have been reported
recently from China, resulting in pseudohigh rates of antifungal
resistance (26). In fact, the erroneously elevated MICs by the Vitek
2 automated reading method not only may lead to inappropriate
selection of antifungal therapy but also depict false rates of high
antifungal resistance in epidemiological studies. Further, the per-
centage of C. auris isolates that showed elevated CAS MICs (1
g/ml) by CLSI-BMD in the present series (37%) declined to 12%
using the Etest. The lower Etest MIC values than CLSI-BMD MIC
values for CAS have also been reported earlier for other Candida
species (27). Recently, the performance of the CAS Etest based on
the recently revised CLSI breakpoints forCandida isolates showed
that 13.1% were misclassified as intermediate or resistant (28).
Also, marked interlaboratory variation has been observed with
both CLSI-BMD and the EUCAST method for CAS susceptibility
(29). In order to investigate the resistance mechanism with respect
to elevated CAS MICs, in the present series we attempted to se-
quence FKS hot spot regions in C. auris isolates using known FKS
C. glabrata primers due to a lack of published genomic data for C.
auris. Although none of the isolates with elevated CAS MICs har-
bored mutations reported for echinocandin-resistant C. glabrata,
the possibility of other mutations not reported so far could not be
ruled out. Future studies on complete genomic analysis are war-
ranted to detect true antifungal resistance in this significant
pathogen.
Finally, C. auris is emerging as a serious multidrug nosocomial
pathogen in many centers in India, which could be reliably and
rapidly identified by MALDI-TOF MS. Notwithstanding the fact
that routine laboratories heavily rely on commercial systems for
identification and antifungal susceptibility testing for yeasts, a
cautionary approach is recommended for isolates showing ele-
vated MICs with these systems.
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